AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30328970
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg mangosteen pericarp per day for 24 weeks
Trial: 17040484
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) chewing gum, 5 mg, 2 pieces, twice a day for 3 months
Trial: 9073005
Drug: Deep inhalation
RxNorm normalized name: Deep Sea Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep inhalation
Trial: 9073005
Drug: Forceful and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forceful and deep inhalation
Trial: 18412958
Drug: Daily acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily acid regurgitation
Trial: 16215331
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone (OxyContin)
Trial: 11940291
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose recombinant tissue-type plasminogen activator (rt-PA) thrombolysis
Trial: 7650092
Drug: MPH (Methylphenidate);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH (Methylphenidate); specific dosage and duration not mentioned
Trial: 2719748
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of muroctasin (L group)
Trial: 1174902
Drug: Aminocaproic acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminocaproic acid 3 g taken six-hourly during menstruation
Trial: 31618495
Drug: Oral taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral taurine for 12 weeks
Trial: 16527639
Drug: Removable appliance
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable appliance with palatal crib combined with high-pull chincup therapy
Trial: 6851273
Drug: Metoprolol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, 200 mg daily
Trial: 21128060
Drug: S-1 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 monotherapy (40 mg/m², orally twice daily, days 1-28, every 6 weeks)
Trial: 17951625
Drug: SFC (salmeterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (salmeterol 50 microg/fluticasone 500 microg, twice daily)
Trial: 2801590
Drug: Liquid cow-milk-based
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid cow-milk-based formula containing 1.3 mumol Cu/L (n = 16)
Trial: 2801590
Drug: Liquid cow-milk-based
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid cow-milk-based formula supplemented with 7.8 mumol Cu/L as Cu sulfate (n = 16)
Trial: 30125376
Drug: 250 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/kg acetylcysteine over 12 hours
Trial: 30125376
Drug: 300 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/kg acetylcysteine over 20 hours
Trial: 28845931
Drug: Adjuvant antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant antioxidant therapy with SpermActin-forte (SA)
Trial: 28845931
Drug: Adjuvant antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant antioxidant therapy with SpermActin-forte (SA) and vitamin complex (VC)
Trial: 25117173
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg once daily and asunaprevir 200 mg twice daily (combination dosing for 14 days)
Trial: 25117173
Drug: Daclatasvir and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir and asunaprevir administered together or alone in HCV patients
Trial: 16119487
Drug: S-ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (1 mg/kg) with priming (0.04 mg/kg of rocuronium)
Trial: 16119487
Drug: S-ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (1 mg/kg) without priming
Trial: 16119487
Drug: Thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4 mg/kg) with priming (0.04 mg/kg of rocuronium)
Trial: 16119487
Drug: Thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4 mg/kg) without priming
Trial: 16119487
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sham priming with saline) with S-ketamine (1 mg/kg)
Trial: 16119487
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sham priming with saline) with thiopentone (4 mg/kg)
Trial: 12296586
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment (full-mouth daily scaling and root planing for 4 consecutive days)
Trial: 12296586
Drug: Weekly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly treatment (once a week for 4 weeks)
Trial: 3092656
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g four times daily
Trial: 6110957
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (25 mg)
Trial: 24074879
Drug: NPLD (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPLD (60 mg/mq iv) plus cyclophosphamide (600 mg/mq iv) every 3 weeks for 4 cycles followed by docetaxel (35 mg/mq iv) plus trastuzumab (4 mg/mq loading dose iv, then 2 mg/mq iv) weekly for 16 weeks
Trial: 15452611
Drug: Epithalamin (peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epithalamin (peptide preparation from the pineal gland)
Trial: 11552904
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg b.d.
Trial: 11552904
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg o.m.
Trial: 27063478
Drug: Ambrisentan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (10 mg per day)
Trial: 24943851
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment Simultaneously Targeting Obesity and Pain (STOP)
Trial: 22627057
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate suspension 0.2% administered QID
Trial: 22627057
Drug: Olopatadine solution
RxNorm normalized name: olopatadine Ophthalmic Solution
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine solution 0.1% administered BID
Trial: 15869587
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation oral contraceptives
Trial: 15869587
Drug: Third generation
RxNorm normalized name: Third generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third generation oral contraceptives
Trial: 12534456
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg day-1 for 3 weeks
Trial: 8570773
Drug: Biperiden (Akineton)
RxNorm normalized name: biperiden hydrochloride Oral Tablet [Akineton]
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biperiden (Akineton) 12 mg/day for 4 weeks
Trial: 8570773
Drug: Glycopyrrolate (Robinul)
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (Robinul) 1 mg/day for 4 weeks
Trial: 8570773
Drug: Biperiden (Akineton)
RxNorm normalized name: biperiden hydrochloride Oral Tablet [Akineton]
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biperiden (Akineton) 12 mg/day for 1 week
Trial: 1700927
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (chemotherapy followed by radiation therapy)
Trial: 535132
Drug: Divided dose
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dose regimen of 25 mg methotrexate taken at 2-hour intervals (total 100 mg)
Trial: 535132
Drug: Single 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 100 mg oral dose of methotrexate
Trial: 23593417
Drug: rhGH 3
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 3 mg daily
Trial: 23593417
Drug: Combination rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination rhGH + rosiglitazone
Trial: 20095368
Drug: D-cycloserine 100
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine 100 mg
Trial: 14985219
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg FeSO(4)
Trial: 10101526
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (0.56 mg intranasally daily for two weeks)
Trial: 7828351
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy for 4 months
Trial: 7828351
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 4 months
Trial: 30415813
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg/d and Solifenacin 10 mg/d
Trial: 30415813
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg/d and Solifenacin 20 mg/d
Trial: 28595339
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT-D)
Trial: 18466078
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hypothyroidism
Trial: 16549905
Drug: AST-120 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (3 g t.i.d.)
Trial: 27754709
Drug: Enzyme-Modified Ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-Modified Ginseng Extract (EMGE) 2,000 mg/day for 4 weeks
Trial: 23363720
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (4 CAD lectures, CAD outpatient visit twice a month, monthly telephone instructions)
Trial: 18264012
Drug: Subcutaneous histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous histamine (1‐10 ng twice a week)
Trial: 18264012
Drug: Oral topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral topiramate (100 mg daily)
Trial: 19841763
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using G-Bond adhesive.
Trial: 19841763
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group using bonding procedures according to manufacturers' instructions for G-Bond adhesive.
Trial: 15206986
Drug: Solifenacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (10 mg) administered in fasting state
Trial: 15206986
Drug: Solifenacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (10 mg) administered in fed state
Trial: 9134633
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (INR 2.5-4.0)
Trial: 9134633
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration (APTT 1.5-2.5 x control)
Trial: 9134633
Drug: Women using
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women using oral contraceptives
Trial: 7898965
Drug: Surfactant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant therapy (two doses of Exosurf rescue surfactant)
Trial: 7898965
Drug: Air placebo
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air placebo (two doses of air)
Trial: 3112934
Drug: Ordinary sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary sugar coated penicillin tablets
Trial: 30666859
Drug: Bioptron light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioptron light treatment in addition to full mouth scaling and root planing (FMSRP)
Trial: 16505499
Drug: 500 or
RxNorm normalized name: C-500 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 or 1,000 mcg chromium daily (chromium picolinate)
Trial: 11757828
Drug: 1.5 L
RxNorm normalized name: NUTREN 1.5 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 L fill volume
Trial: 11757828
Drug: 2.0 L
RxNorm normalized name: NUTREN 2.0 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 L fill volume
Trial: 7957545
Drug: Amiloride 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 15 mg daily
Trial: 22388343
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (0.8 mg)
Trial: 8493625
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol (8 mg)
Trial: 20029224
Drug: Metformin continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin continued throughout pregnancy
Trial: 20029224
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Metformin stopped in first trimester or conceived spontaneously without Metformin)
Trial: 20029224
Drug: Metformin continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin continued in women with prior history of miscarriage
Trial: 788732
Drug: Pralidoxime mesylate
RxNorm normalized name: pralidoxime mesylate
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pralidoxime mesylate (P2S) 750 mg and atropine sulphate 2.0 mg
Trial: 25213055
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg daily for 6 weeks
Trial: 22907440
Drug: Prokinetic with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic with split-dose PEG (100 mg itopride administered twice with each split-dose of PEG)
Trial: 22907440
Drug: Split-dose PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose PEG alone
Trial: 12921618
Drug: Modified anti-shock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified anti-shock programme (urine output maintained at 100 ml/h)
Trial: 12921618
Drug: Traditional resuscitation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional resuscitation formula (urine output maintained at 40 ml/h)
Trial: 12575374
Drug: New Zhengtian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Zhengtian Pill (NZTP)
Trial: 12575374
Drug: Fuguiqin Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuguiqin Capsule (Control)
Trial: 9364538
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m2 for 1 hour every 3 weeks)
Trial: 9364538
Drug: Mitomycin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin (12 mg/m2 every 6 weeks) plus Vinblastine (6 mg/m2 every 3 weeks)
Trial: 3753801
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 micrograms per kilogram of body weight, single oral dose)
Trial: 3892293
Drug: Diethylcarbamazine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (daily for eight days)
Trial: 31638970
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment and radiation for Oral Cancer
Trial: 31638970
Drug: Self-treatment prior
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment prior to specialist consultation
Trial: 31638970
Drug: Treatment initiation
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment initiation after confirmed diagnosis
Trial: 31638970
Drug: Financial expenditure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial expenditure on treatment
Trial: 22453581
Drug: clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clindamycin phosphate 1.2%/BPO 2.5% gel
Trial: 20214078
Drug: Needle retention
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle retention time in acupuncture treatment
Trial: 16249145
Drug: Topical caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical caffeine 10%
Trial: 2852389
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 800 micrograms twice daily
Trial: 2024740
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 3 mg
Trial: 19346952
Drug: Miglustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat (200 mg TID)
Trial: 15338068
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg cimetidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 1)
Trial: 15338068
Drug: 1.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg ranitidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 2)
Trial: 15338068
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine p.o. + 0.1 mg/kg dimetindene i.v. 1 to 2 h before induction of anaesthesia (Group 3)
Trial: 15338068
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml saline solution i.v. 20 min before induction of anaesthesia (Control Group 4)
Trial: 9039510
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) + Oxandrolone (Ox) 0.0625 mg/kg/day po
Trial: 9039510
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) + Testosterone (T) 5 mg i.m. every 14 days
Trial: 3066966
Drug: isoptin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isoptin (10 mg)
Trial: 3066966
Drug: obsidan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: obsidan (5 mg)
Trial: 25790670
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XFC) - 3 pills each time, 3 times a day for 3 months
Trial: 25790670
Drug: SASP (sulfasalazine)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SASP (sulfasalazine) - 4 tablets each time, twice a day for 3 months
Trial: 21612139
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg of Ringer's lactate (RL)
Trial: 21612139
Drug: 15 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL/kg of Ringer's lactate (RL)
Trial: 21612139
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg of Ringer's lactate (RL)
Trial: 19422345
Drug: Oral valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valganciclovir (for 21 days) followed by once daily valganciclovir until day 49
Trial: 19422345
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (twice daily for 21 days)
Trial: 19422345
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (valganciclovir and ganciclovir)
Trial: 16949694
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of dose to the penile bulb and crura
Trial: 15719855
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine (10 mg)
Trial: 11564483
Drug: levodopa 100
RxNorm normalized name: levodopa 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa 100 mg